A prospective, observational study for outcomes and safety profiles of MRI-guided transurethral ultrasound ablation of the prostate for prostate cancer
Not Applicable
Recruiting
- Conditions
- prostate cancer
- Registration Number
- JPRN-UMIN000038291
- Lead Sponsor
- Sapporo Hokuyu Hospital
- Brief Summary
1 out of 5 cases whose 1 year data have been analyzed had cancer recurrence outside of the treated area. Urinary continence and QOL data are good.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Male
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
Patients contraindicated for MRI (patients with intracorporeal metal incompatible with MRI) Patients without histopathological diagnosis of prostate cancer
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Recurrence of prostate cancer until 5 years after the treatment
- Secondary Outcome Measures
Name Time Method PSA value, MRI findings, prostate volume, lower urinary tract symptom, sexual function and quality of life evaluation using following questionnaires (IPSS, OABSS, EPIC, SF-12), voiding function using urodynamic studies, required managements for voiding function, adverse events (urinary incontinence, erectile dysfunction, urethral stricture, urinary tract infection, rectal injury, hematuria, voiding dysfunction, urinary retention, others), learning curve of treatment workflow.